Marshall Wace
EDIT icon

Marshall Wace’s Editas Medicine EDIT Stock Holding History

Marshall Wace’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.6M Buy
2,037,287
+1,826,979
+869% +$5.34M 0.01% 1232
2026
Q1 		$519K Buy
+210,308
New +$445K ﹤0.01% 2432
2025
Q3 		– Sell
-142,008
Closed -$312K – 2993
2025
Q2 		$312K Sell
142,008
-100,368
-41% -$164K ﹤0.01% 2314
2025
Q1 		$281K Buy
+242,376
New +$357K ﹤0.01% 2294
2024
Q4 		– Sell
-63,759
Closed -$217K – 2684
2024
Q3 		$217K Sell
63,759
-385,394
-86% -$1.68M ﹤0.01% 2272
2024
Q2 		$2.1M Sell
449,153
-342,167
-43% -$1.93M ﹤0.01% 1350
2024
Q1 		$5.87M Sell
791,320
-319,882
-29% -$2.66M 0.01% 941
2023
Q4 		$11.3M Sell
1,111,202
-1,083,604
-49% -$9.51M 0.02% 654
2023
Q3 		$17.1M Sell
2,194,806
-643,511
-23% -$5.52M 0.03% 488
2023
Q2 		$23.4M Buy
+2,838,317
New +$24.7M 0.05% 426
2023
Q1 		– Sell
-23,867
Closed -$212K – 2773
2022
Q4 		$212K Buy
+23,867
New +$262K ﹤0.01% 2687
2022
Q2 		– Sell
-17,725
Closed -$337K – 3519
2022
Q1 		$337K Sell
17,725
-368,902
-95% -$6.86M ﹤0.01% 2935
2021
Q4 		$10.3M Buy
+386,627
New +$13.3M 0.02% 844
2019
Q1 		– Sell
-17,905
Closed -$408K – 1800
2018
Q4 		$408K Buy
+17,905
New +$487K ﹤0.01% 1167

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Marshall Wace's EDIT Position: Q2 2026 in Review

Marshall Wace increased its Editas Medicine (EDIT) stake by 869% in Q2 2026, buying an estimated $5.34M and bringing the position to 2,037,287 shares worth $6.6M. The position accounts for 0.01% of the portfolio, ranked #1232.

Marshall Wace first reported a position in EDIT in Q4 2018 and has held it in 14 quarters since. The position peaked at $23.4M in Q2 2023. 216 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Marshall Wace held 2,037,287 shares of Editas Medicine worth $6.6M as of Q2 2026.
  • Marshall Wace bought 1,826,979 Editas Medicine shares in Q2 2026, an estimated $5.34M.
  • Editas Medicine made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #1232 holding.
  • Marshall Wace first reported a position in Editas Medicine in Q4 2018 and has held it in 14 quarters since.
  • Marshall Wace's Editas Medicine position peaked at $23.4M in Q2 2023.
  • 216 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.